Agenus Inc. (NASDAQ:AGEN - Get Free Report) has been given a consensus recommendation of "Hold" by the six brokerages that are presently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $10.00.
Separately, HC Wainwright reiterated a "neutral" rating on shares of Agenus in a research note on Wednesday, January 22nd.
Read Our Latest Stock Report on AGEN
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the stock. EP Wealth Advisors LLC acquired a new position in Agenus in the third quarter valued at $55,000. Point72 DIFC Ltd lifted its holdings in shares of Agenus by 380.0% in the 3rd quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 11,542 shares during the last quarter. Apollon Wealth Management LLC acquired a new stake in shares of Agenus in the 4th quarter valued at about $55,000. HighTower Advisors LLC grew its stake in Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company's stock worth $122,000 after buying an additional 7,530 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its position in Agenus by 52.0% during the third quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company's stock worth $151,000 after buying an additional 9,422 shares during the period. 61.46% of the stock is owned by hedge funds and other institutional investors.
Agenus Stock Down 6.4 %
NASDAQ AGEN traded down $0.24 on Tuesday, hitting $3.50. 390,437 shares of the stock were exchanged, compared to its average volume of 435,433. Agenus has a fifty-two week low of $2.50 and a fifty-two week high of $19.69. The company has a 50-day moving average price of $3.27 and a 200-day moving average price of $4.27. The company has a market cap of $82.11 million, a PE ratio of -0.31 and a beta of 1.30.
About Agenus
(
Get Free ReportAgenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
